Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc. · 141 locations · Updated 2026-11-12
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-10-26
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Syndax Pharmaceuticals · 173 locations · Updated 2026-10-21
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Beat AML, LLC · 31 locations · Updated 2026-09-03
Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML
Shanghai Jiao Tong University School of Medicine · Locations not reported · Updated 2026-08-12
Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-07-07
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
The First Affiliated Hospital of Soochow University · 2 locations · Updated 2026-03-20
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University · Locations not reported · Updated 2025-12-04
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
Peking University People's Hospital · 1 locations · Updated 2025-01-31
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Gruppo Italiano Malattie EMatologiche dell'Adulto · 48 locations · Updated 2024-11-08
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 69 locations · Updated 2026-11-18
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 138 locations · Updated 2026-11-16
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 229 locations · Updated 2026-11-12
Interferon-α Maintenance in Favorable-Risk AML
Peking University People's Hospital · 1 locations · Updated 2026-11-09
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 227 locations · Updated 2026-11-09
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
National Cancer Institute (NCI) · 81 locations · Updated 2026-11-04
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 187 locations · Updated 2026-10-28
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
OHSU Knight Cancer Institute · 1 locations · Updated 2026-10-20
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · Locations not reported · Updated 2026-10-20
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
Medical College of Wisconsin · 1 locations · Updated 2026-10-13
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute · 1 locations · Updated 2026-10-08
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · Locations not reported · Updated 2026-10-07
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · Locations not reported · Updated 2026-10-01
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital · 10 locations · Updated 2026-09-17
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI) · Locations not reported · Updated 2026-09-09
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
Technische Universität Dresden · 18 locations · Updated 2026-08-27
Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia
Christer C Nilsson · 1 locations · Updated 2026-08-17
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Chaser Therapeutics, Inc. · 1 locations · Updated 2026-08-14
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
University of Washington · 1 locations · Updated 2026-08-13
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Sawa Ito, MD · 3 locations · Updated 2026-08-11
HMA-Venetoclax Induction in Newly Diagnosed AML
Pakistan Blood and Marrow Transplant (PBMT) Group · 1 locations · Updated 2026-08-05
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine · 1 locations · Updated 2026-07-24
Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia
University Hospital, Bordeaux · 3 locations · Updated 2026-07-24
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
University of Maryland, Baltimore · 1 locations · Updated 2026-07-01
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-05-13
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Shenzhen University General Hospital · 1 locations · Updated 2026-05-01
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute · 2 locations · Updated 2026-04-01
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Centre Hospitalier Universitaire de Nice · 35 locations · Updated 2026-03-27
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Institut Paoli-Calmettes · 1 locations · Updated 2026-03-13
Showing 1–40 of 100. Older studies
More hematologic trials (126) that list MRD only as a secondary endpoint
A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
Beijing InnoCare Pharma Tech Co., Ltd. · 1 locations · Updated 2026-11-13
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm · 91 locations · Updated 2026-11-12
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Janssen Research & Development, LLC · 270 locations · Updated 2026-11-03
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-10-26
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group · 206 locations · Updated 2026-09-17
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
Ipsen · Locations not reported · Updated 2026-09-10
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
Chinese PLA General Hospital · 1 locations · Updated 2026-08-20
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07
Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML
Ruijin Hospital · Locations not reported · Updated 2026-07-29
DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML
The Second Affiliated Hospital of Kunming Medical University · 1 locations · Updated 2026-07-20
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 locations · Updated 2026-04-13
VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-03-25
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University · 21 locations · Updated 2026-03-20
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Peking University People's Hospital · Locations not reported · Updated 2026-02-12
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland · 119 locations · Updated 2025-08-19
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Yehui Tan · 1 locations · Updated 2025-08-08
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
Princess Maxima Center for Pediatric Oncology · 1 locations · Updated 2025-08-05
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Nanfang Hospital, Southern Medical University · 1 locations · Updated 2025-02-06
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
Shijiazhuang Yiling Pharmaceutical Co. Ltd · Locations not reported · Updated 2023-05-26
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
The First Affiliated Hospital of Soochow University · 2 locations · Updated 2022-08-19
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
PETHEMA Foundation · 21 locations · Updated 2026-11-17
A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML
TuHURA Biosciences, Inc. · Locations not reported · Updated 2026-11-16
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation
Servier · Locations not reported · Updated 2026-11-16
An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)
First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-11-13
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center · 1 locations · Updated 2026-11-12
Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Second Affiliated Hospital of Nanchang University · 1 locations · Updated 2026-11-09
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Uma Borate · 1 locations · Updated 2026-11-09
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington · 1 locations · Updated 2026-11-06
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
UNC Lineberger Comprehensive Cancer Center · 1 locations · Updated 2026-11-05
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center · 3 locations · Updated 2026-10-20
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center · 1 locations · Updated 2026-10-06
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital · 7 locations · Updated 2026-10-05
Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
Florian Kuchenbauer · 1 locations · Updated 2026-10-02
A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
Stichting Hemato-Oncologie voor Volwassenen Nederland · 19 locations · Updated 2026-09-23
Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
Virginia Commonwealth University · 1 locations · Updated 2026-09-21
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center · 1 locations · Updated 2026-09-04
A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-08-26
Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-08-11
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
Vitruviae · Locations not reported · Updated 2026-08-06
VA Consolidation in Intermediate-Risk AML
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-08-06
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-08-06
Study of SA+X in the Treatment of Newly Diagnosed AML
Ruijin Hospital · 1 locations · Updated 2026-07-30
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Fred Hutchinson Cancer Center · 1 locations · Updated 2026-07-20
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Joshua Zeidner · 7 locations · Updated 2026-07-10
Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations
Shen yang · 1 locations · Updated 2026-06-24
Luspatercept for CIA in AML
Guangdong Second Provincial General Hospital · 1 locations · Updated 2026-06-23
Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML
Dongguan People's Hospital · Locations not reported · Updated 2026-06-18
VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.
Hematology department of the 920th hospital · Locations not reported · Updated 2026-06-11
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Kyowa Kirin Co., Ltd. · 20 locations · Updated 2026-06-03
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-05-13
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Chinese PLA General Hospital · 1 locations · Updated 2026-05-08
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Justin Watts, MD · 1 locations · Updated 2026-04-16
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University · 1 locations · Updated 2026-04-14
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech · 1 locations · Updated 2026-04-13
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
Beijing 302 Hospital · 1 locations · Updated 2026-04-07
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Chinese PLA General Hospital · 1 locations · Updated 2026-04-02
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
First People's Hospital of Hangzhou · 1 locations · Updated 2026-04-02
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Gyala Therapeutics · 2 locations · Updated 2026-03-13
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
French Innovative Leukemia Organisation · 20 locations · Updated 2026-03-11
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-03-05
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Nantes University Hospital · 23 locations · Updated 2026-01-30
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
Institute of Hematology & Blood Diseases Hospital, China · 5 locations · Updated 2025-12-26
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-15
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2025-12-01
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Guangdong Provincial People's Hospital · 13 locations · Updated 2025-11-17
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Advesya SAS · 6 locations · Updated 2025-09-18
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
University Hospital Tuebingen · 1 locations · Updated 2025-04-08
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Bio-Path Holdings, Inc. · 9 locations · Updated 2025-03-07
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-01-20
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Advanced BioDesign · 3 locations · Updated 2025-01-20
NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial
Hospital de Clinicas de Porto Alegre · 1 locations · Updated 2025-01-20
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-10-01
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Hospital Municipal São José · 5 locations · Updated 2024-08-05
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Brian Jonas · 4 locations · Updated 2024-05-29
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Akeso · 1 locations · Updated 2024-04-29
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2024-03-05
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Xuzhou Medical University · 1 locations · Updated 2023-11-09
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
Shanghai Tong Ren Hospital · 19 locations · Updated 2023-03-15
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Shanghai Tong Ren Hospital · 4 locations · Updated 2023-03-15
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Virginia Commonwealth University · 1 locations · Updated 2026-11-05
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
Liping Dou · 1 locations · Updated 2026-10-27
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
University of Colorado, Denver · 1 locations · Updated 2026-10-20
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center · 1 locations · Updated 2026-10-19
CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
Liping Dou · 1 locations · Updated 2026-10-02
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center · 1 locations · Updated 2026-09-29
Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-09-18
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
AbbVie · 8 locations · Updated 2026-08-26
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Jacqueline Garcia, MD · 2 locations · Updated 2026-08-26
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine · 1 locations · Updated 2026-08-24
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc. · 45 locations · Updated 2026-08-20
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07
Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-08-06
Leukemia Adapted Protocol
Baylor College of Medicine · 1 locations · Updated 2026-07-15
Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
Nantes University Hospital · 1 locations · Updated 2026-06-25
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute · 2 locations · Updated 2026-06-17
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc. · 17 locations · Updated 2026-06-15
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Peking University People's Hospital · 1 locations · Updated 2026-06-01
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Uma Borate · 4 locations · Updated 2026-05-14
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
David Avigan · 1 locations · Updated 2026-05-05
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Norman J. Lacayo · 9 locations · Updated 2026-04-22
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
GluBio Therapeutics Inc. · 8 locations · Updated 2026-04-13
ABC Maintenance Therapy for AML
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-04-09
Revumenib in Combination With 7+3 + Midostaurin in AML
Richard Stone, MD · 2 locations · Updated 2026-03-25
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Chinese PLA General Hospital · 1 locations · Updated 2026-03-20
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc. · 44 locations · Updated 2026-03-13
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University · 1 locations · Updated 2026-03-12
A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-03-02
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute · 1 locations · Updated 2026-02-27
Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia
University Hospital, Toulouse · 1 locations · Updated 2026-02-04
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Medical College of Wisconsin · 1 locations · Updated 2026-01-12
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Terrence J Bradley, MD · 1 locations · Updated 2026-01-08
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Montefiore Medical Center · 1 locations · Updated 2026-01-08
Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)
University Hospital, Bordeaux · Locations not reported · Updated 2025-12-08
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia
MEI HENG · 1 locations · Updated 2025-11-18
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics · 13 locations · Updated 2025-09-24
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-08-03
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-06-03
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Nanfang Hospital, Southern Medical University · 1 locations · Updated 2025-01-08
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China · 4 locations · Updated 2024-12-30
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
Affiliated Hospital of Nantong University · 1 locations · Updated 2024-11-12
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies
Assistance Publique - Hôpitaux de Paris · 28 locations · Updated 2024-06-26
Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia
Assistance Publique - Hôpitaux de Paris · 1 locations · Updated 2024-05-29
The Patient Cohort of the National Center for Precision Medicine in Leukemia
Assistance Publique - Hôpitaux de Paris · 3 locations · Updated 2024-05-29
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
Ruijin Hospital · 1 locations · Updated 2024-03-26
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2023-06-18
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.